These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17043751)

  • 21. Effect of angiotensin II type 1 (AT1) receptor antagonist on the endothelial dysfunction in spontaneously hypertensive rats in correlation with the nitric oxide system.
    Slaninka-Miceska M; Bogdanska J; Korneti P; Kostova E; Jovanoska E; Petrov S
    Bratisl Lek Listy; 2003; 104(11):342-6. PubMed ID: 15055718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Langleben D; Hirsch AM; Shalit E; Lesenko L; Barst RJ
    Chest; 2004 Oct; 126(4):1377-81. PubMed ID: 15486408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    O'Callaghan DS; Gaine SP
    Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension.
    Douglas SA; Gellai M; Ezekiel M; Ohlstein EH
    J Hypertens; 1994 May; 12(5):561-7. PubMed ID: 7930556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
    Widlitz AC; Barst RJ; Horn EM
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):985-91. PubMed ID: 16292989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat.
    Hofman C; Gabai E; Peleg E; Munter K; Rosenthal T
    Blood Press; 2005; 14(2):114-9. PubMed ID: 16036489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelin antagonism suppresses plasma and cardiac endothelin-1 levels in SHRSPs at the typical hypertensive stage.
    Jesmin S; Zaedi S; Maeda S; Togashi H; Yamaguchi I; Goto K; Miyauchi T
    Exp Biol Med (Maywood); 2006 Jun; 231(6):919-24. PubMed ID: 16741024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.
    Mukaddam-Daher S; Menaouar A; Paquette PA; Jankowski M; Gutkowska J; Gillis MA; Shi YF; Calderone A; Tardif JC
    Hypertension; 2009 May; 53(5):775-81. PubMed ID: 19273740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension.
    Souza R; Martins BC; Jardim C; Cortopassi F; Fernandes CJ; Pulido T; Sandoval J
    Int J Clin Pract; 2007 Jan; 61(1):153-6. PubMed ID: 17229188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelin receptor blockers in cardiovascular disease.
    Rich S; McLaughlin VV
    Circulation; 2003 Nov; 108(18):2184-90. PubMed ID: 14597580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
    Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
    N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sitaxsentan (ICOS-Texas Biotechnology).
    Wu-Wong JR
    Curr Opin Investig Drugs; 2001 Apr; 2(4):531-6. PubMed ID: 11566012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension.
    Opocenský M; Kramer HJ; Bäcker A; Vernerová Z; Eis V; Cervenka L; Certíková Chábová V; Tesar V; Vanecková I
    Hypertension; 2006 Nov; 48(5):965-71. PubMed ID: 17015777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Xin-Ji-Er-Kang formula on 2K1C-induced hypertension and cardiovascular remodeling in rats.
    Guo K; Lan CZ; Yu TT; Huang LL; Wang XH; Pan C; Gao S
    J Ethnopharmacol; 2014 Sep; 155(2):1227-35. PubMed ID: 25063306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
    Inada Y; Murakami M; Kaido K; Nakao K
    Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
    Pathak A; Hanon O; Negre-Pages L; Sevenier F;
    Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the flavonoid fraction of Lithocarpus polystachyus Rehd. on spontaneously hypertensive and normotensive rats.
    Hou SZ; Xu SJ; Jiang DX; Chen SX; Wang LL; Huang S; Lai XP
    J Ethnopharmacol; 2012 Sep; 143(2):441-7. PubMed ID: 22820240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension.
    Vanourková Z; Kramer HJ; Erbanová M; Bäcker A; Cervenka L; Husková Z; Chábová VC; Tesar V; Dvorák P; Malý J; Vanecková I
    Vascul Pharmacol; 2009; 50(5-6):194-9. PubMed ID: 19563737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PGH(2)-TxA(2)-receptor blockade restores vasoreactivity in a new rodent model of genetic hypertension.
    Suzuki H; Ikezaki H; Hong D; Rubinstein I
    J Appl Physiol (1985); 2000 Jun; 88(6):1983-8. PubMed ID: 10846009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.